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Abstract: It aimed to evaluate the renal functions according to the accumulation site 
of amyloid in patients diagnosed with secondary amyloidosis by renal biopsy. Fifty 
patients diagnosed with secondary amyloidosis, who referred to the nephrotic 
syndrome outpatient clinic included in the study. According to the findings of renal 
biopsy, only-glomerular amyloid deposition (group- 1) detected in 9 patients and 
glomerular+ tubulointerstitial deposition (group- 2) identified in 41 patients. Serum 
creatinine, creatinine clearance, and total proteinuria levels compared between 
groups at the time of presentation and on 3rd, 6th, 12th, and 24th months. Initial and 
subsequent serum creatinine, creatinine clearance, and total proteinuria levels not 
found to be significantly different between groups (p>0,05 for all). Among subjects 
with only-glomerular deposition, statistically significant descents in total proteinuria, 
when compared to initial levels, were observed from the beginning of the 6th month 
to the end of the 24th month (p<0,05). On the other hand, subjects with both 
glomerular + tubulointerstitial deposition, statistically significant descents in total 
proteinuria levels observed from the beginning of follow-up to the end of the 24th 
month (p<0,01). In subjects with both glomerular + tubulointerstitial accumulation, a 
statistically significant increase in serum creatinine, compared to baseline levels, 
observed in 12th and 24th months (p<0,01). According to the biopsy findings, 
progressive deterioration of renal functions and an increase in proteinuria were 
higher in patients with both glomerular and tubulointerstitial amyloid deposition than 
patients with only-glomerular removal.  
Keywords: renal biopsy; deposition; secondary amyloidosis 
 
INTRODUCTION 
 Amyloidosis is a disease caused by the extracellular accumulation of a 
fibrillary protein called amyloid in various organs (Westermark et al., 2005). Amyloid 
fibrils may be stored locally and involve almost all organ systems depending on the 
biochemical structure of the amyloid precursor proteins. Amyloid fibril deposition may 
not lead to any significant clinical manifestations, but on the other hand, it may 
accompany severe pathophysiological changes, as well. The disease usually 
progresses between these two extremes (Husby et al.,1994 ). Despite technological 
advances, no clinical, serological, or radiological data have fully substituted renal 
biopsy for the identification of amyloidosis ( Pepys et al.,2001 and Kebbel et al., 
2006 and Bergesio et al., 2007 and Lachmann et al., 2004 ). After the diagnosis of 
amyloidosis, the determination of amyloid type is essential in terms of treatment and 
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prognosis of the disease (Picken et al., 2007 ). Secondary (reactive, modified, or AA) 
amyloidosis most commonly occurs during chronic inflammatory diseases, infections, 
and neoplastic diseases. Familial Mediterranean fever (FMF), chronic obstructive 
pulmonary disease (COPD), rheumatoid arthritis, ankylosing spondylitis, systemic 
lupus erythematosus, behçet's disease, Crohn's disease, and ulcerative colitis are 
among the most common chronic inflammatory diseases. At the same time, 
tuberculosis, osteomyelitis, and bronchiectasis are the frequent infectious and 
thyroid medullary cancer, Hodgkin lymphoma and insulinoma are the numerous 
neoplastic causes (Cohen et al., 1991 and Seldin et al., 2005 and Falk et al., 1997 
and Elżbieta et al., 2019 ). Renal involvement in systemic amyloidosis is a common 
complication and indicates a poor prognosis. Patients present with clinical 
manifestations ranging from proteinuria to nephrotic syndrome, and renal biopsy is 
required in a significant proportion of patients to serve as a diagnostic and also a 
prognostic tool. Therefore, the clinical correlation with the storage type, severity, 
prevalence and clinical reflection of the kidney biopsy will enable the prognosis of the 
disease to predicted  (Lachmann et al., 2004 and Falk et al., 1997 and Elżbieta et al., 
2019 and Lachmann et al., 2007 and Gertz et al., 1991 ).    
The distribution pattern of glomerular amyloid deposits, glomerular 
inflammatory reaction, and tubular atrophy in the renal biopsy are independent risk 
factors for proteinuria level and renal damage (Verine et al., 2007 ). Renal failure 
usually refers to severe glomerular amyloidosis and tubular atrophy. In contrast, 
renal prognosis in patients with renal amyloidosis does not always have a 
morphological explanation (Dikman et al., 1981). To understand how this clinical 
difference occurs, we wanted to clarify the results of amyloid deposition, especially in 
the glomerular and tubulointerstitial space. This study aimed to evaluate the renal 
biopsy findings for the amyloid storage location and according to renal functions of 
patients with secondary amyloidosis.  
 
MATERIALS – METHODS 
Patient population and follow-up 
 Fifty patients admitted to the nephrotic syndrome outpatient clinic of İstanbul 
Göztepe Training and Research Hospital from 1994 to 2010 and diagnosed with 
secondary amyloidosis after undergoing renal biopsy included in the study. The 
ethics committee approved the review of İstanbul Göztepe Training and Research 
Hospital. Age, sex, serum urea, creatinine, 24-hour urine total protein (glomerular 
filtration rate, clinical signs at presentation (such as edema, hematuria, proteinuria, 
oligoanurated hypertension) and an indication of renal biopsy (nephrotic syndrome, 
nephritic syndrome and asymptomatic urine findings, etc.) were collected 
retrospectively. Serum urea, creatinine, and 24-hour urine total protein performed by 
photometric measurement methods (Architect C16000 clinical biochemistry analyzer, 
Abbott®, USA). In calculating the glomerular filtration rate, the formula proposed by 
the Study Group's Modification of Diet in Renal Disease (MDRD) was used ( Levey 
et al., 1999 ). The relevant medical history like underlying chronic diseases (FMF, 
COPD, rheumatoid arthritis, Behçet's disease, ankylosing spondylitis, bronchiectasis, 
and tuberculosis, etc.) and currently used antiproteinuric drugs (angiotensin-
converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) 
provided. 
 Renal biopsy report of each case obtained and findings of glomerular 
involvement, tubular involvement, tubular atrophy, and interstitial fibrosis recorded. 
Based on renal biopsy, amyloid involvement dichotomized into two groups according 
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to whether the involved compartment was only-glomeruli (Group-1) or both glomeruli 
and tubulointerstitium (Group-2). Stage 1, in the scoring system of renal amyloidosis, 
corresponds to Group-1 in our study, whereas stage 2 and 3 match with group-2 
(Sen et al., 2010 ). 
The follow-up time started from the month of renal biopsy (baseline) and continued 
with data collection on 3rd, 6th, 12th, and 24th months. The final status of the 
patients, including active disease, remission (complete and partial), and relapse, was 
considered to evaluate prognosis and treatment outcome (Table-1). 
  
Table-1: Active, remission and relapse criteria of the disease 
Active proteinuria Proteinuria over 3.5 g/day on 3 consecutive days 
Complete remission Less than 0.2 g/day of proteinuria for 3 consecutive days 
Partial remission Proteinuria between 0.2-3.5 g/day for 3 consecutive days 
Proteinuria relapse In patients at complete remission, proteinuria over 0.2 g/day 
for at least one week 
Nephrotic syndrome 
relapse 
Proteinuria more significant than 3.5 g/day for at least one 
week in patients at complete or partial remission 
 
Pathology 
The following morphological findings used in Group-1 and Group-2 
classification: 
1-Amyloid involvement of the glomerular compartment (total number of glomeruli, 
number of globally sclerotic glomeruli, glomerular participation type, a diameter of 
glomeruli, degree of glomerular amyloid, accumulation of glomerular nodular amyloid 
(segmental/global presence)  
2-Amyloid involvement of the tubular-interstitial compartment (vasa recta 
involvement, tubular atrophy/fibrosis, appearance, quality and severity of interstitial 
inflammation, accumulation and diameter of interstitial amyloid, amyloid deposition in 
the tubular basement membrane damage)  
Statistical analysis 
NCSS (Number Cruncher Statistical System) 2007 & PASS 2008 Statistical 
Software (Utah, USA) program used for statistical analysis. The normality of 
distribution examined by using the Kolmogorov-Smirnov test. Along with descriptive 
statistical methods (mean, standard deviation), for comparison of quantitative and 
normally distributed data. Although normal distribution was determined, non-
parametric tests used due to the relatively small sample size. Mann-Whitney U t-test 
used for between-group differences. Wilcoxon Signed Ranks test used for within-
group differences. The chi-square test used to evaluate the qualitative data. 
Significance was assessed at p <0.05. 
 
RESULTS AND DISCUSSION 
Baseline characteristics and morphological findings 
The mean age at the time of diagnosis was 46.92( 13.3) years (M: F=1.27: 1). 
The most common cause of secondary amyloidosis was FMF, followed by COPD 
and rheumatoid arthritis (Table-2). While only glomerular involvement detected in 9 
of 50 cases (Group-1), 41 of them had both glomerular and tubulointerstitial 
relationships (Group-2). Glomerulosclerosis was observed in 17 of the cases, while 
mesangial proliferation and inflammatory cells in the glomeruli observed in the 
remaining 33 cases. Tubular atrophy (82%) was common and mostly mild (76%). 
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Inflammatory reaction was present in 32% of the cases; inflammatory cells were 
generally of the mixed (mononuclear + polymorphonuclear) type. 
 
Table 2: Diseases causing AA (Secondary) amyloidosis 
 
 
Underlying Chronic Disease 
          Biopsy Finding    
Total Group-1  Group-2 
n:9 (%) n:41 (%) n:50 (%) 
FMF 8 (88,9%) 20 (48,8%) 28 (56,0%) 
COPD 0 (%0) 8 (19,5%) 8 (16,0%) 
Romatoid artrit 1 (11,1%) 5 (12,2%) 6 (12,0%) 
Ankylosing spondylitis 0 (0%) 2 (4,9%) 2 (4,0%) 
Gout 0 (0%) 2 (4,9%) 2 (4,0%) 
Chronic pyelonephritis 0 (0%) 2 (4,9%) 2 (4,0%) 
Tuberculosis                            0 (0%) 2 (4,9%) 2 (4,0%) 
Behcet 's disease 0 (0%) 1 (2,4%) 1 (2,0%) 
Hodgkin Lymphoma 0 (0%) 1 (2,4%) 1 (2,0%) 
Ulcerative colitis 0 (0%) 1 (2,4%) 1 (2,0%) 
 FMF; familial mediterranean fever 
 COPD; Chronic obstructive pulmonary diseases 
 
Clinicopathological correlation 
Total proteinuria 
 There was no statistically significant change in total proteinuria in the 3rd 
month, compared to baseline, in Group-1 patients (p> 0.05). However, when the 
absolute proteinuria values examined from the beginning of the 6th month to the end 
of the 24th month, statistically significant decreases compared to baseline were 
observed (p <0,05). About group-2, statistically, significant descents in total 
proteinuria levels were seen from the beginning of follow-up to the end of the 24th 
month (p<0,01). There was no significant difference between the groups (p> 0,05) 
(Table-3, Figure-1). 
 
Table 3: Evaluation of Total Proteinuria (mg / 24 h) based on Biopsy Finding 
 
Total Proteinuria (mg/24 h) 
Biopsy Finding 
p* Group-1 Group-2 
Mean±SD Mean±SD 
Baseline 5,11±5,17 4,71±3,46 0,785 
3rd month 2,45±2,54 3,78±2,84 0,160 
6th month 1,88±1,77 3,92±3,54 0,119 
12 th month 1,78±2,07 3,35±3,21 0,091 
24 th month 1,41±1,69 2,94±2,76 0,082 
Baseline-3rd month 0,086 0,031  
Baseline-6th month 0,028* 0,048  
Baseline-12th month 0,028* 0,048  
Baseline-24th month 0,018* 0,002  
           *Mann-Whitney U t-test was used for between-group differences. Wilcoxon 
 Signed Rank test was used for within-group differences. 
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Figure-1: Total proteinuria (gr / 24 h) levels by months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum creatinine levels 
There was no statistically significant change in creatinine levels in Group-1 
patients at the 3rd, 6th, 12th, and 24th months compared to baseline (p> 0.05). 
Regarding the change in creatinine levels in group-2 patients, there was no 
significant difference (p> 0.05) between baseline and 3rd and 6th months. On the 
contrary, in the 12th and 24th months, a statistically significant rise in creatinine was 
seen compared to baseline levels (p <0.01). 
Glomerular filtration rate 
Twelve percent of all cases had an end-stage renal failure at the time of renal 
biopsy. In Group-1, there was no statistically significant change in MDRD GFR 
between the baseline and the 3rd, 6th, 12th, and 24th months’ rates (p> 0.05). 
However, MDRD GFR significantly decreased in Group-2 cases at 12th and 24th 
months compared to baseline (p> 0.05) (Table -4 and Figure-2) 
 
Figure-2: MDRD GFR (mL / min / 1.73 m2) changes by months 
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Table 4: Evaluation of MDRD GFR (mL / min / 1.73 m2) 
 
MDRD GFR 
Biopsy Finding 
    p* Group-1  Group-2 
Mean±SD Mean±SD 
Baseline 72,67±32,05 65,34±30,61 0,522 
3rd month 68,89±36,61 64,90±30,05 0,730 
6th month 69,78±31,24 62,53±29,47 0,512 
12th month 73,67±35,47 55,85±25,81 0,087 
24th month 71,87±32,74 57,25±29,57 0,084 
Baseline-3rd month 0,268 0,815  
Baseline-6th month 0,531 0,102  
Baseline-12th month 0,740 0,001  
Baseline-24th month 0,953 0,009  
   MDRD GFR; Modification of Diet in Renal Disease glomerular filtration rate.  
   *Mann-Whitney U t-test was used for between-group differences.  
   Wilcoxon Signed Rank test was used for within-group differences 
 
Drugs used 
 Use of ACEi, ARB and the combination of ACEi and ARB as anti-proteinuric 
treatment were compared between groups and not found to be statistically significant 
(Table-5). 
 
Table 5: Use of ACEi, ARB and ACEi + ARB combination 
 
 
Biopsy Finding 
P* Group-1 Group-2 
n (%) n (%) 
Baseline 
treatment 
ACE 4 (50%) 26 (66,7%) 
0,575 ARB 1 (12,5%) 5 (12,8%) 
ACE+ARB 3 (37,5%) 8 (20,5%) 
3rd month 
treatment 
 
ACE 3 (33,3%) 23 (57,5%) 
0,265 ARB 1 (11,1%) 6 (15%) 
ACE+ARB 5 (55,6%) 11 (27,5%) 
6th month 
treatment 
ACE 3 (33,3%) 22 (56,4%) 
0,362 ARB 1 (11,1%) 5 (12,8%) 
ACE+ARB 5 (55,6%) 12 (30,8%) 
12th month 
treatment 
ACE 2 (22,2%) 17 (43,6%) 
0,457 ARB 2 (22,2%) 8 (20,5%) 
ACE+ARB 5 (55,6%) 14 (35,9%) 
24th month 
treatment 
ACE 3 (37,5%) 17 (47,2%) 
0,449 ARB 1 (12,5%) 9 (25%) 
ACE+ARB 4 (50%) 10 (27,8%) 
       ACEi; angiotensin converting enzyme inhibitors,  
       ARB;angiotensin receptor blockers.  
       *Chi- square test was used for between-group differences 
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Evaluation of the final status 
During the renal biopsy, 46% of the patients were in remission (complete and 
partial), and 54% were inactive proteinuria phase. At the end of the 12th month, 28% 
of patients had progressive proteinuria, 58% had a remission, 2% had proteinuria 
relapse, and 12% had nephrotic syndrome relapse. At the end of 24 months, the 
remission rate increased to 70% (12% complete and 59% partial), while the actual 
proteinuria rate decreased to 18%. 
Among patients with only-glomerular involvement, 55.6% had progressive 
proteinuria at the time of biopsy. At the end of 24 months, all but one patient had 
complete or partial remission. In patients with both glomerular and tubulointerstitial 
involvement, 53.7% had progressive proteinuria at baseline while this rate was 
36.6% at the end of the 3rd month, 31.7% at the end of the 6th month, and 23.1 % at 
the end of the 24th month. Finally, at the end of the 24th month, 69.2% of the 
patients were in remission (Table-6). 
 
Table 6: Final Assessment of Proteinuria Levels 
 
Final status 
Biopsy Finding 
Group-1 Group-2 
n (%) n (%) 
Baseline 
Active proteinuria 5 (%55,6) 22(%53,7) 
Complete remission 0 1 (%2,4) 
Partial remission 4 (%44,4) 18 (%43,9) 
3rd month 
Active proteinuria 2 (%22,2) 15 (%36,6) 
Complete remission 2 (%22,2) 1 (%2,4) 
Partial remission 5 (%55,6) 19 (%46,3) 
Proteinuria relapse 0 1 (%2,4) 
NS relapse 0   5 (%12,2) 
6th month 
Active proteinuria 1 (%11,1) 13 (%31,7) 
Complete remission 2 (%22,2)            4 (%9,8) 
Partial remission 5 (%55,6) 19 (%46,3) 
NS relapse           1 (51,1)   5 (%12,2) 
12th month 
Active proteinuria 1 (%11,1) 13 (%31,7) 
Complete remission 1 (%11,1) 4 (%9,8) 
Partial remission 5 (%55,6) 19 (%46,3) 
Proteinuria relapse 1 (%11,1) 0 
NS relapse 1 (%11,1) 5 (%12,2) 
24th month 
Active proteinuria 0 9 (%23,1) 
Complete remission 3 (%33,3) 4 (% 9.7) 
Partial remission 5 (%55,6) 25 (% 60.9) 
Proteinuria relapse 0 1 (%2,6) 
NS relapse 1 (%11,1) 2 (%5,1) 
NS; Nephrotic syndrome 
 
 In this study involving patients diagnosed with secondary amyloidosis, kidney 
functions were evaluated according to the renal amyloid storage location, whether in 
only-glomerular or both glomerular+tubulointerstitial compartment, in 24 months. In 
the end, no significant difference found about serum creatinine, MDRD creatinine 
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clearance, and total proteinuria levels between the predefined groups. However, 
within each group, throughout 24 months, in comparison to the baseline month, the 
renal loss was found to be higher in glomeruli + tubulointerstitium-involved patients 
compared to only-glomeruli-involved patients. It is also noteworthy to state that a 
considerable proportion of the patients (56%) with secondary amyloidosis had to 
coexist FMF in the present study emphasizing the relatively high frequency of this 
disease in Turkey. 
 The number of studies in the literature on the amount and localization of 
amyloid stored in the kidney is limited (Shiiki et al., 1988 and Watanabe et al., 1975 
and Falck et al., 1983; and Westermark et al., 1979). Existing studies on 
morphological findings predicting proteinuria levels in secondary amyloidosis have 
been established linear correlation with the severity of glomerular amyloid deposition 
(Verine et al., 2007 and Kaplan et al., 1999). Proteinuria severity correlates with the 
presence of podocyte destruction rather than the amount of amyloid in the glomeruli 
(Dikman et al., 1981 ). In our study, although glomerular and tubulointerstitial 
involvement not evaluated separately, there was a numerical difference between the 
groups in terms of total proteinuria decrease. Although this situation was not 
statistically significant, the decline compared to baseline was approximately 3.5 
times for group 1 and less than half for group 2. In a study, closely resembling our 
sample size and primary etiology, the results of renal function change and 
proteinuria reduction found to be similar. (Abdallah et al., 2013). While evaluating 
these changes in proteinuria levels, intensive use of ACEi, ARB, or ACEi, together 
with ARB, should not be ignored in both study groups. In a study where ACEi 
(ramipril) and ARB (telmisartan) were used together as a dual effect, or only ACEi or 
ARB used as monotherapy, a significantly higher incidence of hyperkalemia 
observed in the double blockage arm. ( Heerspink et al., 2014). Currently, the 
combination of ACEi and ARB is no longer in use because of the considerable risk of 
hyperkalemia. Since the study covers the years 1994-2010, the combination therapy 
had used in Turkey at that time.  
 Dikman et al. reported a rapid loss of renal function in patients with renal 
amyloidosis with tubular atrophy (Dikman et al., 1981 ). Verine et al. also regarded 
the tubular atrophy and the prevalence and type of amyloid deposition as 
independent variables for renal function (Verine et al., 2007 ). Supporting these 
trials, in the present study, glomerular amyloid deposition coupled with 
tubulointerstitial involvement, which defined as group-2, exhibited a prominent renal 
loss, particularly after 1st year in the follow-up. However, in the study arm with only-
glomerular responsibility, the renal reserve was better preserved. 
 Results from analysis, including 97 patients with primary and secondary 
amyloidosis, ended up with a five and 10-year survival rate of 30% and 20%, 
respectively. The authors concluded that the strongest prognostic determinants of 
renal survival are amyloid-induced renal damage and serum creatinine level at the 
time of biopsy. Furthermore, AA amyloidosis found to be far more associated with 
tubulointerstitial loss as compared to AL amyloidosis ( Sasatomi et al., 2001 ). 
However, Dikman et al. argued that there is not always a morphological explanation 
for the frequently irreversible decrease in renal function (Dikman et al., 1981 ). This 
may be a result of the rate of development of amyloidosis, they added. Because the 
risk and price of development of amyloidosis vary according to genotypes 
(Nakamura et al., 2006), nevertheless, a recent article uncovered the conclusion that 
renal damage not expected to be associated with amyloid deposition (Kuroda et al., 
2017 and Kuroda et al., 2019). 
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 Selection bias resulting from retrospective work is our main limitation. The 
other limitation is the small number of patients included. The third one is the lack of 
standardization in the antiproteinuric treatment agents among patients and last 
relates to the absence of rebiopsies during the follow-up, to determine whether a 
non-glomerular involvement occurs in group-1. 
Conclusion 
 According to the biopsy findings, progressive deterioration of renal functions 
and an increase in proteinuria were higher in patients with both glomerular and 
tubulointerstitial amyloid deposition than patients with only-glomerular removal. 
Therefore the pathology report in patients with renal amyloidosis should incorporate 
detailed morphological findings aiding better prognostication (the type of glomerular 
amyloid accumulation and renal damage score = degree of glomerular accumulation 
+ tubulointerstitial accumulation) rather than be used as a general diagnostic assay. 
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